Journal
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
Volume 10, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s40164-020-00186-y
Keywords
-
Categories
Ask authors/readers for more resources
The FDA approval of Ivosidenib and Enasidenib has introduced new possibilities for the treatment of acute myeloid leukemia (AML) in elderly patients. The successful case of a 60-year-old woman achieving complete response to combination therapy with Azacytidine, Enasidenib, and Venetoclax marks a significant advancement in the treatment of refractory AML.
Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available